

---

REMARKS

The amendments to the claims are to correct typographical errors. No new matter has been added.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.


By   
Carolyn S. Elmore  
Registration No. 37,567  
Telephone: (978) 341-0036  
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: 5/2/08


MARKED UP VERSION OF AMENDMENTSClaim Amendments Under 37 C.F.R. § 1.121(c)(1)(ii)

12. (Amended) The polymer [of] or copolymer of Claim 11, wherein the polymer or copolymer is characterized by repeat units of the formula:




wherein  $R_7$  is a substituted or unsubstituted lower alkylene group having from 1 to about 24 carbon atoms and each  $X^-$ , separately or taken together, is a physiologically acceptable anion.

13. (Amended) The polymer [of] or copolymer of Claim 11 wherein the polymer or copolymer is characterized by repeat units of formula X or XI:




(X)




(XI).

38. (Amended) The polymer or copolymer of [C claim] Claim 36 wherein the polymer or copolymer is characterized by repeat units of formula XVI or XVII:



(XVI)



-30-

TABLE 1  
Polymer MIC(ug/ml)

	Formula #											
S. aureus (ATCC 29213)												
MRSA (5 strains) <sup>(1)</sup>												
GISA (5 strains) <sup>(2)</sup>												
E. faecalis (ATCC 29212)												
VRE (4 strains)												
P. aeruginosa (ATCC 27853)												
Candida*												
B. cepacia												
Oral pathogens **												
C.difficile												
H. pylori (Win)												
E. coli (ATCC 25922)												
S. marcescens												
	VIII	0.65	1-2	1	1-3	10.4	0.65-1.3	41.5	0.65	0.2	1.3	3
II	0.31	1.9	≤0.125	0.31	0.3	1.3	1.3-2.6	5.2	nd	<0.16	0.2	.65
IV	0.65	2.2-3.8	nd	0.65	2-2.6	2.6	0.32-2.6	5.2	nd	nd	3	1.3
II	1.8	1-2.6	nd	1	1-2	9	3-28	28	nd	nd	1	1
III	1.4	0.4-1.8	nd	3	1-3	9	1-3	28	nd	nd	2	3
XII	0.31	0.3-0.5	nd	0.3	0.3	0.31	0.16-2.6	41.5	nd	nd	nd	2.6
XIX	0.65	1	0.5	1	1-3	0.65	1.3-2.6	41.5	<10	nd	1	2.6
XX	1.3	2.2-3	16	1	1-3	1.3	2.6	5.2	<10	<0.16	0.4	1.3
XXIII	1	1.4-2.2	nd	1	1-3	9	3	9	nd	nd	1	3
IX+	1	nd	nd	0.3	nd	83	1-9	28	nd	nd	nd	3
IX++	1	1	nd	3	3-20	83	1-9	9	nd	nd	0.7	3
	0.65	nd	8	1.25	nd	5.2	0.65-1.3	5.2	<10	2.5	1.3	2.6

\* 3 strains C. glabrata, 6 strains C. albicans, 2 strains C. tropicalis, 2 strains C. Krusei; \*\* including: *Actinobacillus actinomycetemcomitans*, *Porphyromonas gingivalis*, *Prevotella intermedia*, *Campylobacter rectus*, *Treponema dentitcola*, *Streptococcus intermedius*, *Fusobacterium nucleatum*, *Streptococcus gordonii*, and *Actinomyces viscosus*; <sup>1</sup> methicillin resistant *Staphylococcus aureus*; <sup>2</sup> glycopeptide intermediate *Staphylococcus aureus*; + (where R7 is butyl), ++(where R7 is decyl), +++(where R7 is dodecyl)